- Allergic Rhinitis
- Asthma
- Bronchiectasis
- COPD
- Cystic Fibrosis
- ILD/IPF
- Influenza
- Inhalation Devices
- PAH
- Tuberculosis
Webcasts
Expert's Viewpoint
- Why is 1st Generation Antihistamine No Longer Indicated to Treat Allergic Rhinitis or Urticaria?
- How Common Are Allergic Diseases Like Allergic Rhinitis and Urticaria and What is its Impact on Quality of Life of Children?
- Webinar Snippet: What are The Current Guideline Recommendations on Management of Allergic Rhinitis and Urticaria?
- Webinar Snippet: Why Should Bilastine Be Preferred in Children with Allergic Rhinitis and Urticaria?
- Webinar Snippet: How Safe is Bilastine?
- Allergic Rhinitis and Asthma: One Airway, One Disease
- Allergic Rhinitis: Practical Considerations
Our Publications
- Billargic (Bilastine Oral Solution) Monograph
- Intranasal Steroids for Allergic Rhinitis: A Guide for Practitioners
- Allergic Rhinitis- From Beginning to End
- Allergy Express - Issue 8
- Allergic Rhinitis and Rhinosinusitis: The Link
- Allergy Express- Issue 5
- Allergy Express: Issue 3
- Bronchonasal Crosstalk
- Minimal Persistent Inflammation in Allergic Rhinitis
- Intranasal Steroids in Nasal Polyposis
- ARIA 10' Guidelines Booklet
Key Trials
- Fluticasone is Comparable to Mometasone in Alleviating Symptoms of Allergic Rhinitis
- Azelastine Hydrochloride and Fluticasone Propionate Combination Nasal Spray Offers Better and Complete Symptom Relief in Allergic Rhinitis
- Montelukast Combined with Antihistaminics Might Benefit Patients with Resistant Allergic Rhinitis
- Rapid Onset of Action of Azelastine hydrochloride and Fluticasone propionate Combination Nasal Spray
- Evaluating the Safety and Efficacy of Fluticasone Furoate Nasal Spray in Asian Pediatric Patients with Perennial Allergic Rhinitis
- Montelukast Improves Symptom Severity Score in Allergic Rhinitis
- Azelastine hydrochloride and Fluticasone propionate Combination Nasal Spray Safe and Effective in Allergic Rhinitis
- Effect of Bilastine on Cognitive Functions at 4000 Meters Altitude Simulated in Hypobaric Chamber
- Pharmacokinetic and Safety Analysis Support Bilastine Dose of 10 mg in Children Aged 6-11 Years with Allergic Rhinoconjunctivitis and Urticaria
- Efficacy and Superiority of Intranasal Azelastine and Fluticasone Combination Spray as Compared to Monotherapy in Allergic Rhinitis
- In AR, Montelukast-Fexofenadine Offers Superior Efficacy at a Higher Cost than Montelukast-Levocetirizine
- Bilastine Effective and Safe in Perennial Allergic Rhinitis: A Japanese Phase 3 Study
- Self-Prepared Hypertonic Nasal Saline Irrigation Alleviates Nasal Congestion and Improves Quality of Life in Allergic Rhinitis
- Intranasal Spray Containing Azelastine hydrochloride and Fluticasone propionate is Safe and Well Tolerated in Children with Allergic Rhinitis
- CARAS Survey: Co-existence of Allergic Rhinitis and Asthma in Indian Patients
Conference Proceedings
Patient Education
Clinical Tools
Webcasts
- Diagnosis and Monitoring of Asthma and COPD in the Era of Social Distancing
- National Inhaled Drug Delivery Forum (Day 2)
- Respiratory Crosstalks: Exploring the Cardiopulmonary Link
- ICS LABA in Pediatric Asthma
- Severe Asthma Conclave 2020 – A Web Series on Clinical Paradigms: Part 1
- Refining the Choice of ICS in OAD Management
- OAD Management: Spotlight on Patient-centered Care
- Home Nebulization: Current and Future Aspects (Panel Discussion)
- Aerosol Therapy for Asthma – Time for a Relook
- Novel Approach for Uncontrolled Asthma Management
- A New Era in Inhaled Drug Delivery
- Role of Nebulisation Therapy in Acute Asthma Management
- Asthma Diagnosis and Management
- Important New Asthma Recommendation for Primary Care Physicians
- FAQs on Pediatric Asthma (2019)
- Nebulization: Altogether Better for Acute Asthma (June 2018; Dr. Suryakant Tripathi)
- FAQs on Pediatric Asthma (2018)
- Small Airways
- Phenotyping and Biomarkers
- Sputum Inflammometry to Treat Airway Diseases – A Clinical Case
- Expert Views on GINA Guidelines - Step Wise Approach on Pediatric Asthma
- Full Support for a Flourishing Asthma Practice
- PURVIEW - Asthma: Beyond Prescription
- Nebulization Beyond Exacerbation
- Aerosol Drug Delivery
- Asthmatic Patients in the ICU A Focus on Acute Severe Asthma and Status of Asthmatics
- Nebulization in Clinical Practice
- Patient Safety: Are We Missing Something?
- Asthma Management beyond Prescription
- Good Nebulization Practice (2015)
- PURVIEW: Inhaler Devices - From Principles to Real Life Implications
- Asthma Management: What Lies Ahead
- Asthma Diagnosis and Management (in Hindi)
- Management of Severe Asthma Using Inflammometry
- Demystifying Nebulization
- PURVIEW – Turbinates to Terminal Bronchioles: The One Airway Concept
- Nebulization: Altogether Better for Acute Asthma (Webcast in Hindi)
- Helping You Deliver in Your Asthma Practice
- Why Asthma is Good for Your Practice
- PURVIEW - Understanding Spirometry
- Transforming Asthma Management from Science to Practice
Expert's Viewpoint
- Take Home Messages from Guideline Recommendations
- Precautions for Patient on Home Nebulization
- Patient Criteria for Home Maintenance Nebulization
- Webinar Snippet: Where Would You Use Ciclesonide in the Management of Asthma?
- Webinar Snippet: Extra Fine Versus Non Extrafine Formulation in Obstructive Lung Disease: Is There an Advantage?
- Webinar Snippet: What Are the Advantages of Ciclesonide?
- Webinar Snippet: Add-on Extra Fine Ciclesonide in Patients with Poorly Controlled Asthma
- Webinar Snippet: Advantages of Add-on Ciclesonide in Difficult to Treat Asthmatics
- Webinar Snippet: PK/PD Considerations While Choosing ICS
- Webinar Snippet: Clinical Considerations While Choosing ICS
- Managing Acute Asthma with pMDI + Spacer in Real Life
- Webinar Snippet: Changing mindset – Rethinking pMDI+Spacer Usage
- Webinar Snippet: Current Recommendations on Inhaler Devices to Reduce Risk of Infection
- Webinar Snippet: Is pMDI+Spacer Equivalent to Nebulizer?
- Webinar Snippet: Does Every Child with Exacerbation Require a Nebulizer?
- Webinar Snippet: Alternative Management of Acute Exacerbations for Adult OAD Patients
- Practicing Peak Flow Meter as A Home Monitoring Tool
- Webinar Snippet: Switching to Extra -Fine Particle Formulations – Does it Help Improve Asthma Control?
- Webinar Snippet: Switching to BAIs – Option to Consider in Patients with Uncontrolled Asthma
- Webinar Snippet: Choosing the Right Biologic in Severe Asthma
- Webinar Snippet: Role of Omalizumab in Severe Asthma – Selecting the Right Patient
- Webinar Snippet: Choosing the Right Patient for Biologic Therapy
- Does Omalizumab Therapy Reduce the Healthcare Cost Burden in Severe Asthma?
- For How Long Should Omalizumab Therapy Be Continued?
- Differential Diagnosis of Cough
Our Publications
- Emzumab (Omalizumab) Monograph
- Ciclohale (Ciclesonide) Product Monograph
- Foracort Synchrobreathe (Formoterol fumarate dihydrate and Budesonide) Infoguide
- Asthma Management in The Acute Setting: Role of pMDI + Spacer
- A Clinician’s Guide
- Spacers with pMDI- A Support to Inhalation Therapy
- Aerosol Therapy for Obstructive Airways Diseases: Focus on pMDI+Spacer
- Ease‑of‑use, preference, confidence, and satisfaction with Revolizer, a novel dry powder inhaler, in an Indian population
- Physicians’ Knowledge and Practice of Inhalation Therapy – An Indian Perspective
- Inhalation Technique Errors with Metered-Dose Inhalers Among Patients with Obstructive Lung Diseases: A Systematic Review and Meta-Analysis
- Are You Prescribing the Correct Inhalation Device?
- Incorrect Inhaler Techniques: A Perpetual Challenge!
- How to Help Patients Optimise Their Inhaler Technique?
- Seroflo (Salmeterol + Fluticasone propionate) Multi-haler Monograph
- Flohale (Fluticasone Propionate) 50 mcg Inhaler: Datasheet
- Inhaled Drug Delivery Systems
- Severe Asthma: A Clinician’s Guide
- Optimizing Inhaled Drug Delivery – Focus on Spacers
- Technical Dossier – Minizerostat spacer
- Inhalation Devices: Guide for Paramedics
- Asthma – Answers to Clinical Questions (Volume 2)
- Asthma – Answers to Clinical Questions (Volume 1)
- Check and Correct: A Handbook for Better Inhaler Technique
- Principles of Inhalation Therapy
- Selection of Inhaler Devices
Our Research
- Performance of Revolizer®, using Formoterol/Budesonide* Rotacaps®
- Comparison of In-vitro Performance of Huf Puf Kit© with Transpacer VM
- Doctors’ Perception of Diagnosis and Management of Asthma in Malaysia: A Survey of Doctors
- Design in-vitro Performance of an Advanced Discrete Multidose Dry Powder Inhaler: Multihaler™(60 doses)
- A Comparison of Lung Deposition and Device Resistance of Two Discrete Multidose Dry Powder Inhalers: Multihaler™ (60 doses) and Accuhaler™
Key Trials
- Omalizumab Improves Lung Function and Reduces Eosinophils in Adolescents with Allergic Asthma
- Higher Efficacy and Drug Adherence with Ciclesonide as Step-Down Therapy than Budesonide in Mild to Moderate Asthma
- Improved Lung Function Parameters with Combination of Salmeterol / Fluticasone in Treatment of Bronchial Asthma: An Open Label, Multicentre, Non-Comparative Study
- GOLDEN Trial 5: Long-term Safety of Nebulized Glycopyrrolate in Moderate to Very Severe COPD patients
- GOLDEN Trial 3 & 4: Efficacy and Safety of Nebulized Glycopyrrolate in Moderate to Very Severe COPD patients
- Efficacy of Omalizumab Similar in Severe Allergic Asthmatics Irrespective of the Eosinophilic Counts
- Efficacy of As-Needed Budesonide-Formoterol in Mild Asthma Management
- A Systematic Literature Analysis on Prevalence of Small Airways Disease in Adult Asthmatic Patients
- Efficacy of Beclomethasone Dipropionate /Formoterol Administered by Pressurized Metered-Dose Inhalers: A Clinical Update
- Comparative Efficacy of Beclomethasone/Formoterol Versus Budesonide/Formoterol Therapy in Asthma
- Better Efficacy to Safety Ratio with Fluticasone Propionate than Beclomethasone Dipropionate and Budesonide in Asthma
- Beclomethasone Dipropionate/Formoterol Extrafine Formulation Ensures High Drug Deposition in the Lungs
- Physicians’ Perception on Patterns of Diagnosing and Managing Asthma: A Survey in Myanmar
- Perception of Doctors about Diagnosis, Management and Facing the Challenges with their Patients with Asthma: An Observation-Based Survey in Nepal
- Budesonide–Formoterol More Effective than SABA Alone in Mild Asthmatic Patients
- As-Needed Budesonide–Formoterol Non-inferior to Maintenance Budesonide in Patients with Mild Asthma
- Doctors’ Perception of Diagnosis and Management of Asthma in Malaysia: A Survey of Doctors
- Maintenance and Reliever Therapy with Budesonide/Formoterol Might Reduce the Rate of Severe Exacerbations in Patients with Persistent Asthma
- Real World Clinical Evaluation of Formoterol/Fluticasone Delivered via Revolizer in Persistent Asthma
- Long Term Treatment with Omalizumab May be Helpful in Patients with Severe Allergic Asthma
- Patients with Uncontrolled Persistent Asthma despite GINA Step 4 Therapy Might Benefit with Addition of Omalizumab in their Treatment Regimen
- i-Prefer Study: Indian Patients’ Preference, Based on Ease-of-use, Confidence and Satisfaction with the Revolizer
- POSEIDON: Insight into the Reasons for which the Patients Visit Primary Health-Care Practitioners in India
Patient Education
- Find Out If Your Child’s Cough is More than Just a Cough
- Are You Ignoring Your Cough?
- Do’s & Don’ts for Asthma Patients
- How to use the Inhaler?
- How to use the Revolizer?
- How to use the Rotahaler?
- How to use Zerostat VT™ Spacer?
- Childhood Asthma
- Adult Asthma – English
- breathefree.com – A Unique Patient Education Initiative
- Asthma Par Vijay
- Adult Asthma – My Days of Living in Tension with Asthma are Over!
- Attack Asthma
- Breathe-o meter
- Are you a Smart Mother?
- When is Cough not just a Cough?
Clinical Tools
Guidelines
- GINA: Global Initiative for Asthma – Global Strategy for Asthma Management and Prevention: Guideline (2020)
- GINA: Recommendations on Asthma Management (2020 Update)
- GINA: Recommendations About Reliever Medications in Steps 3-5 (2019 Update)
- ARIA: Next Generation Allergic Rhinitis and Its Impact on Asthma (2019)
- GINA: Asthma Management and Prevention (2019)
- GINA: Asthma Management and Prevention (2018)
- ARIA: Allergic Rhinitis and it’s Impact on Asthma Guidelines : Revision (2016)
- BTS/SIGN: British Guideline on the Management of Asthma (2016)
- GINA: Global Initiative for Asthma - Pocket Guide for Asthma Management and Prevention in Children 5 Years and Younger (2015)
- ERS/ATS: Definition, Evaluation and Treatment of Severe Asthma: International Guidelines (2014)
- WHO/GA2LEN/AllerGen: ARIA (Allergic Rhinitis and its Impact on Asthma): An Update (2008)
Webcasts
- Treatable Traits in Bronchiectasis
- Newer Concepts in the Treatment of Bronchiectasis
- Role of Nebulised Antibiotics: Current Concepts and Future Perspective
- Case Based Discussions: Immuno-deficient Bronchiectasis
- Case based Discussions - Surgery in Bronchiectasis
- Case Based Discussions - NTM Bronchiectasis
- Case Based Discussions- ABPA Bronchiectasis
- Treatment of Bronchiectasis: Current Concepts on Management of COPD - Bronchiectasis Overlap
- Treatment of Bronchiectasis: Current Concepts on Non - Pharmacological Management of Bronchiectasis
- Treatment of Bronchiectasis: Current Concepts - Management of Exacerbation
- EMBARC Registry for Bronchiectasis: Where Are We Now?- Indian Arm
- Bronchiectasis - Microbiological Aspects
- Bronchiectasis - The Newer Insights in New Era
Clinical Tools
Webcasts
- Improving CV Outcomes in COPD
- Why is My COPD Patient Not Responding to Standard Treatments?
- Diagnosis and Monitoring of Asthma and COPD in the Era of Social Distancing
- Newer Paradigms in COPD Management
- National Inhaled Drug Delivery Forum (Day 2)
- Respiratory Crosstalks: Exploring the Cardiopulmonary Link
- OAD Management: Spotlight on Patient-centered Care
- Aerosol Therapy for Asthma – Time for a Relook
- COPD beyond drugs – The Vital Role of Pulmonary Rehabilitation
- A New Era in Inhaled Drug Delivery
- Shifting Gears in the Management of COPD
- Focus on Oxidative Stress in the Lungs
- Nebulization Beyond Exacerbation
- Two Tough Years in the Life of COPD Patient - A Case Report
- Preventing the Fall…Minimising Exacerbations in COPD
- Aerosol Drug Delivery
- COPD: Learn from the Experts
- Nebulization in Clinical Practice
- Long Term Nebulization Therapy - An Evolving Treatment Paradigm in OADs
- Patient Safety: Are We Missing Something?
- The Many Faces of COPD
- Good Nebulization Practice (2015)
- PURVIEW: Inhaler Devices - From Principles to Real Life Implications
- Improving Outcomes... Earlier the Better in COPD
- Demystifying Nebulization
- Acute Exacerbation of COPD (AECOPD): Management and Prevention: A Case-Based Discussion
- PURVIEW - Systemic Manifestation of COPD
- Early Intervention in the Clinical Course of COPD - The Sooner the Better
- Managing Refractory Cough
- Approaching an Elderly Patient with Breathlessness
- Effective, Adjuvant & Neglected Therapies in COPD
- PURVIEW - Understanding Spirometry
- PURVIEW - COPD 2012
- Inhalation Devices: Do We Really Know Enough?
- PURVIEW - COPD Updates
- Towards Reliable Drug Delivery, for the Real World
- Heart Failure and COPD: Managing Both in a Patient
- Co-Morbidity in Lung Disease in the Elderly
- Preparing for Air Travel: Overcoming Problems in Patients with Chronic Respiratory Disease
- Evidence, Guidelines, Habit: What Should Drive Our Practice?
- COPD in Non-Smokers
- COPD in 2010: Real Progress for a Progressive Disease
- Focus on Oxidative Stress in the Lungs
Expert's Viewpoint
- Efficacy & Safety Of Novel Nebulized Glycopyrrolate For The Treatment Of COPD- GOLDEN Studies
- Inhaled Medication: Which Device For Which Patient?
- Nebulized Glycopyrrolate Advantage And Disadvantage
- Alleviating Night-Time Symptoms Unmet Need Of COPD Patients
- Glycopyrrolate Is More Potent Than Indacaterol
- Glycopyrrolate Bronchodilator With A Rapid Onset Of Action And For A Prolonged
- Glycopyrrolate Bronchodilator With A Faster Onset Of Action Than Tiotropium
- Nebulized Glycopyrronium Shows Greater Selectivity Affinity For The M3 Receptors Over The M2 Receptors Than Tiotropium
- Webinar Snippet: Where Would You Use Ciclesonide in the Management of Asthma?
- Webinar Snippet: Extra Fine Versus Non Extrafine Formulation in Obstructive Lung Disease: Is There an Advantage?
- Webinar Snippet: What Are the Advantages of Ciclesonide?
- Webinar Snippet: Add-on Extra Fine Ciclesonide in Patients with Poorly Controlled Asthma
- Webinar Snippet: Advantages of Add-on Ciclesonide in Difficult to Treat Asthmatics
- Webinar Snippet: PK/PD Considerations While Choosing ICS
- Webinar Snippet: Clinical Considerations While Choosing ICS
- Webinar Snippet: Changing mindset – Rethinking pMDI+Spacer Usage
- Webinar Snippet: Current Recommendations on Inhaler Devices to Reduce Risk of Infection
- Webinar Snippet: Is pMDI+Spacer Equivalent to Nebulizer?
- Webinar Snippet: Does Every Child with Exacerbation Require a Nebulizer?
- Webinar Snippet: Alternative Management of Acute Exacerbations for Adult OAD Patients
- Role of Maintenance Nebulization in Management of COPD
- Differential Diagnosis of Cough
- Home Nebulization: A Useful Alternative in COPD Drug Delivery
Our Publications
- Ciclohale (Ciclesonide) Product Monograph
- Foracort Synchrobreathe (Formoterol fumarate dihydrate and Budesonide) Infoguide
- A Clinician’s Guide
- Aerosol Therapy for Obstructive Airways Diseases: Focus on pMDI+Spacer
- Glycohale Respules (Glycopyrrolate) Monograph
- Glycohale – F Product Monograph
- Ease‑of‑use, preference, confidence, and satisfaction with Revolizer, a novel dry powder inhaler, in an Indian population
- Physicians’ Knowledge and Practice of Inhalation Therapy – An Indian Perspective
- Inhalation Technique Errors with Metered-Dose Inhalers Among Patients with Obstructive Lung Diseases: A Systematic Review and Meta-Analysis
- Are You Prescribing the Correct Inhalation Device?
- Incorrect Inhaler Techniques: A Perpetual Challenge!
- How to Help Patients Optimise Their Inhaler Technique?
- Seroflo (Salmeterol + Fluticasone propionate) Multi-haler Monograph
- Complementing COPD Management Through Smoking Cessation
- Pulmonary Rehabilitation - An Insight
- Inhaled Drug Delivery Systems
- TIOTROPIUM 2018: Unfolding 15 Years of Evolution
- Optimizing Inhaled Drug Delivery – Focus on Spacers
- Technical Dossier – Minizerostat spacer
- Nistami (Indacaterol maleate + Glycopyrronium bromide) Dossier
- Air Pollution: Should We Care About the Air We Breathe?
- Inhalation Devices: Guide for Paramedics
- Check and Correct: A Handbook for Better Inhaler Technique
- Principles of Inhalation Therapy
- Selection of Inhaler Devices
- COPD Management Beyond the Lungs:Heart Failure
- Good Nebulization Practice (GNP)
- Revolizer: The Next Generation Novel Single Dose Dry Powder Inhaler
- Integrated Dose Indicators: Technical Aspects and Functional Specifications
- COPD Management Beyond the Lungs: Osteoporosis
- Foracort Respules (Formoterol fumarate dihydrate plus Budesonide) Monograph
- Seroflo (Salmeterol Xinafoate plus Fluticasone Propionate) Inhaler with Dose Counter Monograph
- Maxiflo (Formoterol Fumarate Dihydrate plus Fluticasone Propionate) Inhaler with Dose Counter Monograph
- Revolizer Monograph
- Inhaled Drug Delivery Systems
Our Research
- Performance of Revolizer®, using Formoterol/Budesonide* Rotacaps®
- Evaluation of the Demographics, Diagnosis and Monitoring, Management, Device Usage and Adherence Among COPD Patients: A Survey of Doctors in Nepal
- Evaluation of the Demographics, Diagnosis and Monitoring, Management, Device Usage and Adherence among COPD Patients: A Survey of Doctors in Malaysia
- Design in-vitro Performance of an Advanced Discrete Multidose Dry Powder Inhaler: Multihaler™(60 doses)
- A Comparison of Lung Deposition and Device Resistance of Two Discrete Multidose Dry Powder Inhalers: Multihaler™ (60 doses) and Accuhaler™
- Spirometry - Underutilized in India
- Efficacy of Tiotropium in Patients with COPD
- Safety and Efficacy of Tiotropium + Formoterol in Patients with COPD
- Safety and Efficacy of Tiotropium Rotacaps in Patients with COPD
- Safety and Efficacy of Ipratropium + Salbutamol in Patients with COPD
- Tiotropium + Formoterol More Effective than Ipratropium + Salbutamol in COPD
Key Trials
- Triple Therapy Beneficial in Smokers and Non-Smokers with COPD – An Indian Real-World Study
- Nebulized Glycopyrrolate Reduces the Risk of Clinically Important Deterioration in Moderate-to-Severe COPD
- A Real-World Indian Study Demonstrates Efficacy and Safety of Triple Therapy in COPD Patients
- Risk Factors for Frequent Exacerbations in Chronic Obstructive Pulmonary Disease
- LABA/LAMA Combination Therapy vs Monotherapy in Patients with Symptomatic COPD
- Lung Function and Exacerbations with Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler in COPD
- Is Health Status and Symptom Burden at Baseline Related to the Risk of Exacerbation in COPD?
- Beclomethasone Dipropionate/Formoterol Extrafine Formulation Ensures High Drug Deposition in the Lungs
- Evaluation of the Demographics, Diagnosis and Monitoring, Management, Device Usage and Adherence Among COPD Patients: A Survey of Doctors in Nepal
- Evaluation of the Demographics, Diagnosis and Monitoring, Management, Device Usage and Adherence among COPD Patients: A Survey of Doctors in Malaysia
- Budesonide/Formoterol Combination Superior to Fluticasone/Salmeterol in Preventing Exacerbations in COPD Patients: PATHOS Study
- Tiotropium Associated with Improved Lung Function in Asian Patients with COPD – UPLIFT Subgroup Analysis
- i-Prefer Study: Indian Patients’ Preference, Based on Ease-of-use, Confidence and Satisfaction with the Revolizer
- UPLIFT: A 4-Year Trial of Efficacy and Safety of Tiotropium in Chronic Obstructive Pulmonary Disease
- POSEIDON: Insight into the Reasons for which the Patients Visit Primary Health-Care Practitioners in India
Patient Education
Clinical Tools
Guidelines
- GOLD: Global Strategy for Prevention, Diagnosis and Management of COPD (2020)
- GOLD: Global Strategy for Prevention, Diagnosis and Management of COPD (2019)
- GOLD: Global Strategy for Prevention, Diagnosis and Management of COPD (2019) (Key Changes)
- GOLD: Global Strategy for Prevention, Diagnosis and Management of COPD (2018)
- ERS/ATS Guidelines: Management of COPD Exacerbations (2017)
- GOLD: A Strategy for The Management of COPD (2017)
- ATS/ACCP: Liberation from Mechanical Ventilation in Critically Ill Adults (2016)
- An Official American Thoracic Society / European Respiratory Society Statement: Research Questions in COPD (2015)
- GOLD: Global Strategy for Diagnosis, Management, and Prevention of COPD: An Update (2014)
- ATS/ERS: Key Concepts and Advances in Pulmonary Rehabilitation: Official Statement (2013)
- ICS/NCCP: Diagnosis And Management Of Chronic Obstructive Pulmonary Disease: Guidelines (2013)
- ATS: Novel Risk Factors and the Global Burden of Chronic Obstructive Pulmonary Disease: Official Statement (2010)
- BTS: Intermediate Care—Hospital-at-Home in Chronic Obstructive Pulmonary Disease: Guidelines (2007)
- ERS: The Assessment of Cough: Guidelines (2007)
- ERS: Recommendations on the Use of Exercise Testing in Clinical Practice ERS Task Force Report (2007)
- IPCRG: Diagnosis of Respiratory Diseases in Primary Care: Guideline Paper (2006)
- ATS/ERS: ATS/ERS Task Force Standardisation of Lung Function Testing: General Considerations for Lung Function Testing (2005)
- ATS/ERS: ATS/ERS Task Force Standardisation of Lung Function Testing: Interpretative Strategies for Lung Function Tests (2005)
- ATS/ERS: ATS/ERS Task Force Standardisation of Lung Function Testing: Standardisation of Spirometry (2005)
- ATS/ERS: ATS/ERS Task Force Standardisation of Lung Function Testing: Standardisation of the Measurement of Lung Volumes (2005)
Webcasts
- IPF Management in 2020 (Focus and Interaction on New ERS Statement)
- Demystifying Chronic HP
- Progressive-Fibrosing ILD: How Our Management Approach is Changing
- CT Imaging in ILD- How Computer Aided Diagnostics (CAD) with AI Will Change the Way We Work and Report
- Establishing a Diagnosis of IPF
- Interstitial Lung Disease: A Simpler Approach to Management
- DLD 2015 Update: Case Presentations
- DLD 2015 Update: The End-stage ILD Patient: Communicating, Palliating and Referral for Transplant
- DLD 2015 Update: Hypersensitivity Pnemonitis - A Few Key Messages
- DLD 2015 Update: Rheumatology and Diffuse Lung Disease - What the Pulmonologist Must Know
- DLD 2015 Update: Sarcoidosis Management - Problems and Solutions
- DLD 2015 Update: IPF Management in 2015
- DLD 2015 Update: NSIP – What do We do from There?
- DLD 2015 Update: The IIPs – What You Cannot Afford NOT to know in Pulmonary Pathology Today
- DLD 2015 Update: IPF - Confirming and Communicating the Diagnosis
- DLD 2015 Update: ILD - The Indian Scenario
- DLD 2015 Update: How Accurate is CT in Idiopathic Interstitial Pneumonias?
- ILD in Connective Tissue Disease
- A Year of Change in Idiopathic Pulmonary Fibrosis
- On A New Path in Idiopathic Pulmonary Fibrosis
- Pulmonary Hypertension in Interstitial Lung Disease
Expert's Viewpoint
- Rationale For Use of Antifibrotics in PF ILD and Who Will Benefit From Antifibrotics
- Definition of PF ILD, Which subtypes of ILD have PF-ILD phenotype and what is their estimated proportion
- Is Tissue Necessary to Diagnose Fibrotic ILD?
- Why Does Diagnosis Matter and Importance of Finding Fibrosis on Histopathology
- Differential Diagnosis of Cough
Our Publications
Key Trials
- Nintedanib Reduces Decline in Lung Function in Idiopathic Pulmonary Fibrosis
- Real World Experience with Pirfenidone on Tolerability and Survival: Indian Study
- Pirfenidone Improves Objective and Subjective Cough Measures in Patients with Idiopathic Pulmonary Fibrosis
- Impact of Pirfenidone on Respiratory-related Hospitalizations in Patients with Idiopathic Pulmonary Fibrosis
- Pirfenidone Reduces Disease Progression in Patients with Idiopathic Pulmonary Fibrosis – ASCEND Trial
- Pirfenidone - A Promising Option in the treatment of IPF
Guidelines
- Diagnosis and Detection of Sarcoidosis An Official American Thoracic Society Clinical Practice Guideline (2020)
- ATS/ERS/JRS/ALAT: Clinical Practice Guideline for Diagnosis of Idiopathic Pulmonary Fibrosis (2018)
- ATS/ERS: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias: An Update (2013)
- ATS: The Clinical Utility of Bronchoalveolar Lavage Cellular Analysis In Interstitial Lung Disease: A Clinical Practice Guideline (2012)
- ATS/ERS/JRS/ALAT: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management (2011)
- ATS/ERS: International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias (2002)
- ATS/ERS: Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment (2000)
Our Publications
Key Trials
- High Rates of Clinical Recovery with Remdesivir in Pregnant Women Hospitalized with Severe COVID-19
- Does Remdesivir Provide a Benefit on Clinical Status for Patients Hospitalized with Moderate COVID-19 Pneumonia?
- Remdesivir Improves Survival Outcomes in ICU Patients with COVID-19 under Mechanical Ventilation
- Efficacy and Safety of Remdesivir 5 Days Course verses 10 Days Course in Treatment of Patients with Severe Covid-19 Disease
- Remdesivir Shortens Time to Recovery in Patients Hospitalized with COVID-19
- Compassionate Use of Remdesivir to Treat Patients with Severe Covid-19
- Early Intervention with Remdesivir Associated with Clinical Improvement in Severe COVID-19 Patients
Patient Education
Clinical Tools
Webcasts
Expert's Viewpoint
- Webinar Snippet: What Precautions Need To Be Taken By Patients Taking Nebulization At Home?
- Webinar Snippet: Is It Appropriate To Share The Nebulizer In This Current Pandemic?
- Webinar Snippet: What Are The Patient Profiles For Nebulization In Current Pandemic?
- Webinar Snippet: Do All Nebulizers Have Equal Risk For Spreading Virus In Current Pandemic?
- Webinar Snippet: What Precautions Need To Be Taken While Nebulizing A Patient In Clinic Settings?
- Webinar Snippet: Is There Any Case-Study To Prove That Infection Risk Is Not Due To Nebulization?
- Webinar Snippet: What Recommendations Did CDC And BTS/NICE Made Concerning The Spread Of Infection Via Nebulizer In This Pandemic?
- Webinar Snippet: Is It Safe To Do Nebulization In Current Pandemic Era?
- Webinar Snippet: What Is The Infection Risk Involved With Nebulizers For Spreading The Virus To HCW Or Bystanders?
Our Publications
Webcasts
- New Trends in The Diagnosis and Management of Pulmonary Hypertension
- Medical Management of Chronic Thromboembolic Pulmonary Hypertension
- Aetiopathology and Prevention of CTEPH
- Caring of Patients: Beyond Medical Management
- Role of CT Pulmonary Angiogram and MRI in PAH
- Connective Tissue Associated Pulmonary Hypertension
- Interventions for PH: An Overview
- Aetiology and Pathobiology of PH due to Left Heart Diseases
- Understanding from Indian Registries
- Short Introduction to the Current Medications for Management of PH
- Screening and Diagnostic Strategies to Identify Early PAH - PH due to Rheumatological Disease
- Medical Management of PH due to Left Heart Disease
- Echocardiographic Evaluation of PAH: What is New?
- Exercise Testing and Conditioning in PH
- Cardiac Catheterization: Is it Necessary?
- Medical Management of PAH: How to Choose the Best Treatment?
- Risk Stratification and Medical Management of Pulmonary Hypertension
- Hemodynamic Definitions and Updated Classification of Pulmonary Hypertension [6th World Pulmonary Hypertension Symposium]
- PAH Summit: Expanding Scope, Exploring Possibillities
- PURVIEW - Pulmonary Hypertension
- Pulmonary Hypertension in Interstitial Lung Disease
- The New Era in PAH
Expert's Viewpoint
Our Publications
- Pulmonary Arterial Hypertension in Digital Ulcers
- Pulmonary Hypertension in Pregnancy
- Heart Failure Associated with PAH
- Hospitalization in PAH
- Combination Therapy - Pulmonary Arterial Hypertension
- PAH associated Congenital Heart Disease
- Risk Stratification & REVEAL risk score in Pulmonary Arterial Hypertension Management
- Rioteph (Riociguat) Monograph
- Opsutan (Macitentan) Monograph
- Endobloc (Ambrisentan) Monograph
- PAH: An Update for Rheumatologists
Key Trials
- Anticoagulation Management Post-PEA in Patients with CTEPH: The Current Scenario
- Risk Stratification in PAH with a Comprehensive Echocardiographic Method
- Infants with PPHN Burdened with Increased Morbidity and Mortality Risk in the First Year of Life
- Long Term Treatment with Riociguat Sustains Clinical Benefits for upto One Year in CTPH
- Riociguat Improves Clinical Outcomes in Chronic Thromboembolic Pulmonary Hypertension
- Macitentan and Riociguat Upfront Combination Therapy Improves Hemodynamics and Clinical Outcomes in Patients with PAH
- Treatment with Macitentan Reduced the Risk and Rate of Hospitalizations in Patients with PAH
- Treatment with Macitentan Reduces Morbidity and Mortality in Patients with Pulmonary Arterial Hypertension – SERAPHIN Study
